Kelley Lauren Coffman, MD, on the Next Steps for a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs

Video

The hospitalist at Memorial Sloan Kettering Cancer Center spoke about the next steps for a study which evaluated patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE.

Study findings presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium revealed that investigators saw a meaningful disease control rate among patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE (Lutathera).

In an interview with CancerNetwork®, Kelley Lauren Coffman, MD, a hospitalist at Memorial Sloan Kettering Cancer Center, explained what she believes are the next steps for this research.

Transcription:

Our group has a particular interest in identifying genetic or biomarkers that might help beforehand to predict a patient’s response to therapy. Even in our study [and] in our review of these patients, we looked at the last 2 years. We had access to genetic sequencing, and about two-thirds of the tumors [by] a basic genetic review [demonstrated] mutations…similar to what we expected for well-differentiated tumor types. In the future, going forward, we’d really like to see if there’s a way to identify either genetic or biomarkers that might predict response or resistance to this therapy so that beforehand, you could really identify which patients are going to benefit without subjecting them to the toxicities.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content